Literature DB >> 17392598

GH secretion in a cohort of children with pseudohypoparathyroidism type Ia.

L de Sanctis1, J Bellone, M Salerno, E Faleschini, M Caruso-Nicoletti, M Cicchetti, D Concolino, A Balsamo, F Buzi, L Ghizzoni, C de Sanctis.   

Abstract

Pseudohypoparathyroidism type Ia (PHP-Ia) is characterized by Albright's hereditary osteodistrophy (AHO) and resistance to hormones that act via the alpha subunit of the Gs protein (Gsalpha) protein, ie PTH, TSH, FSH/LH, and, as recently described in limited series, GHRH. However, the current lack of data on GHRH secretion, obesity and short stature included in the AHO phenotype hampers interpretation of GH secretory status and its effects on these subjects. We evaluated GH secretion after GHRH plus arginine (Arg) stimulus, IGF-I levels and anthropometric features in an exclusively pediatric population of 10 PHP-Ia subjects. Of our PHP-Ia children, 5 out of 10 (50%) showed impaired GH responsiveness to the provocative test, with a lower prevalence than the 75-100% previously reported. A negative correlation (p=0.024) was found between GH secretion and body mass index (BMI), whereas no correlation emerged between GH and IGF-I values (p=0.948). Height and growth velocity did not significantly differ between GH-deficient and GH-sufficient subjects. In the 5 GH-deficient patients, GHRH resistance could arguably be responsible for hormonal impairment; however, 3 of them were obese, showing normal stature and IGF-I levels: the increased BMI in these subjects could influence GH secretion and its effects. In conclusion, GH deficiency is frequent among PHP-Ia children and its prevalence is variable, two factors indicating that GH secretory testing should be part of the routine management of this patient group. It could be argued that GHRH resistance is the pathogenetic mechanism in most patients, but further studies on GHRH secretion are needed to define which values can be considered as raised. Lastly, because BMI has been indicated as a major determinant of evoked adult GH response to provocative testing, GH levels related to increased BMI also in childhood could be helpful in defining GH assessment in obese or overweight PHP-Ia children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392598     DOI: 10.1007/BF03347406

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

Review 1.  GNAS locus and pseudohypoparathyroidism.

Authors:  Murat Bastepe; Harald Jüppner
Journal:  Horm Res       Date:  2005-02-09

2.  Early manifestation of calcinosis cutis in pseudohypoparathyroidism type Ia associated with a novel mutation in the GNAS gene.

Authors:  Felix G Riepe; Wiebke Ahrens; Nils Krone; Regina Fölster-Holst; Jochen Brasch; Wolfgang G Sippell; Olaf Hiort; Carl-Joachim Partsch
Journal:  Eur J Endocrinol       Date:  2005-04       Impact factor: 6.664

3.  Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation.

Authors:  J M Nakamoto; A T Sandstrom; A S Brickman; R A Christenson; C Van Dop
Journal:  Am J Med Genet       Date:  1998-05-26

4.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

5.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.

Authors:  B E Hayward; A Barlier; M Korbonits; A B Grossman; P Jacquet; A Enjalbert; D T Bonthron
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

6.  Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan.

Authors:  M R Valetto; J Bellone; C Baffoni; P Savio; G Aimaretti; L Gianotti; E Arvat; F Camanni; E Ghigo
Journal:  Eur J Endocrinol       Date:  1996-11       Impact factor: 6.664

7.  Body composition and spontaneous growth hormone secretion in normal short stature children.

Authors:  J E Abdenur; C V Solans; M M Smith; C Carman; M T Pugliese; F Lifshitz
Journal:  J Clin Endocrinol Metab       Date:  1994-02       Impact factor: 5.958

8.  Multiple associated endocrine abnormalities in a patient with pseudohypoparathyroidism type 1a.

Authors:  M Shima; O Nose; K Shimizu; Y Seino; H Yabuuchi; T Saito
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

9.  Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis.

Authors:  María Gabriela Ballerini; María Gabriela Ropelato; Horacio Mario Domené; Patricia Pennisi; Juan Jorge Heinrich; Héctor Guillermo Jasper
Journal:  J Pediatr Endocrinol Metab       Date:  2004-05       Impact factor: 1.634

10.  Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.

Authors:  S Loche; C Pintor; M Cappa; E Ghigo; R Puggioni; V Locatelli; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05
View more
  8 in total

Review 1.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

2.  Genetic and epigenetic alterations in the GNAS locus and clinical consequences in Pseudohypoparathyroidism: Italian common healthcare pathways adoption.

Authors:  L de Sanctis; F Giachero; G Mantovani; G Weber; M Salerno; G I Baroncelli; M F Elli; P Matarazzo; M Wasniewska; L Mazzanti; G Scirè; D Tessaris
Journal:  Ital J Pediatr       Date:  2016-11-21       Impact factor: 2.638

Review 3.  Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder.

Authors:  Serap Turan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

4.  Identification of a novel GNAS mutation in a case of pseudohypoparathyroidism type 1A with normocalcemia.

Authors:  Xiao-Dan Long; Jing Xiong; Zhao-Hui Mo; Chang-Sheng Dong; Ping Jin
Journal:  BMC Med Genet       Date:  2018-07-30       Impact factor: 2.103

5.  Pseudohypoparathyroidism: application of the Italian common healthcare-pathway for a homogeneous clinical approach and a shared follow up.

Authors:  Daniele Tessaris; Elisa Bonino; Giovanna Weber; Malgorzata Wasniewska; Domenico Corica; Marco Pitea; Giuseppe Scirè; Manuela Caruso-Nicoletti; Danilo Fintini; Luisa de Sanctis
Journal:  Ital J Pediatr       Date:  2021-03-04       Impact factor: 2.638

6.  Different AHO phenotype in a Chinese family with a novel GNAS missense variant: a case report.

Authors:  Qing Zhou; Bin Liang; Qing-Xian Fu; Hui Liu; Chao-Chun Zou
Journal:  Ital J Pediatr       Date:  2022-07-23       Impact factor: 3.288

7.  Follow-up Findings in a Turkish Girl with Pseudohypoparathyroidism Type Ia Caused by a Novel Heterozygous Mutation in the GNAS Gene.

Authors:  Sezgin Şahin; Olaf Hiort; Susanne Thiele; Olcay Evliyaoğlu; Beyhan Tüysüz
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-07-18

Review 8.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.